In addition, CHRAC1 expression level was increased in cisplatin resistant ovarian cancer cell lines and lung cancer tumor tissues, and CHRAC1 disruption inhibited the migration and invasion of cisplatin resistant ovarian cancer cells and H1299 lung cancer cells (Wang et al., 2021a; Yang et al., 2021). Here, CHRAC1 is linked to ovarian carcinoma.